A study of sertraline in dialysis (ASSertID): a protocol for a pilot randomised controlled trial of drug treatment for depression in patients undergoing haemodialysis

BMC Nephrology

Ken Farrington⁶  David Wellsted³  Benjamin Spencer⁴  Naomi Fineberg⁵  Ayman Guirguis⁵  Andrew Davenport¹  Maria da Silva Gane⁶  Joseph Chilcot⁸  Clara Day⁷  Michael Almond²  Karin Friedli³ 

[1] University College London Centre for Nephrology, Royal Free Hampstead NHS Trust, Rowland Hill Street, London NW3 2PF, UK;Southend University Hospital NHS Foundation Trust, Prittlewell Chase, Westcliff – On – Sea, Essex, SSO ORY, UK;Centre for Lifespan and Chronic Illness Research, Department of Psychology, School of Life and Medical Sciences, University of Hertfordshire, College Lane Campus, Hatfield AL10 9AB, UK;South London and Maudsley NHS Foundation Trust, Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK;Hertfordshire Partnership University NHS Foundation Trust, Rosanne House, Welwyn Garden City AL8 6HG, UK;Renal Unit, Lister Hospital, East & North Herts NHS Trust, Coreys Mill Lane, Stevenage SG1 4AB, UK;Department of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, Birmingham B15 2TH, UK;Health Psychology Section, Psychology Department, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, 5th floor Bermondsey Wing, Guy’s Campus, London Bridge, London SE1 9RT, UK

关键词: Feasibility RCT;    Sertraline;    Haemodialysis;    End stage renal disease;    Depression;   

Others  :  1231144
DOI  :  10.1186/s12882-015-0170-x

 received in 2015-09-17, accepted in 2015-10-14,  发布年份 2015

【 摘 要 】

Background

The prevalence of depression in people receiving haemodialysis is high with estimates varying between 20 and 40 %. There is little research on the effectiveness of antidepressants in dialysis patients with the few clinical trials suffering significant methodological issues. We plan to carry out a study to evaluate the feasibility of conducting a randomised controlled trial in patients on haemodialysis who have diagnosed Major Depressive Disorder.

Methods/Design

The study has two phases, a screening phase and the randomised controlled trial. Patients will be screened initially with the Beck Depression Inventory to estimate the number of patients who score 16 or above. These patients will be invited to an interview with a psychiatrist who will invite those with a diagnosis of Major Depressive Disorder to take part in the trial. Consenting patients will be randomised to either Sertraline or placebo. Patients will be followed-up for 6 months.

Demographic and clinical data will be collected at screening interview, baseline interview and 2 weeks, and every month (up to 6 months) after baseline. The primary outcome is to evaluate the feasibility of conducting a randomised, double blind, placebo pilot trial in haemodialysis patients with depression. Secondary outcomes include estimation of the variability in the outcome measures for the treatment and placebo arms, which will allow for a future adequately powered definitive trial. Analysis will primarily be descriptive, including the number of patients eligible for the trial, drug exposure of Sertraline in haemodialysis patients and the patient experience of participating in this trial.

Discussion

There is an urgent need for this research in the dialysis population because of the dearth of good quality and adequately powered studies. Research with renal patients is particularly difficult as they often have complex medical needs. This research will therefore not only assess the outcome of anti-depressants in haemodialysis patients with depression but also the process of running a randomised controlled trial in this population. Hence, the outputs of this feasibility study will be used to inform the design and methodology of a definitive study, adequately powered to determine the efficacy of anti-depressants in patient on haemodialysis with depression.

Trial registration

ISRCTN registry ISRCTN06146268 and EudraCT reference: 2012-000547-27.

【 授权许可】

   
2015 Friedli et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]National and Centre-specific Analyses. Nephron. 2013; 2015(129 Suppl 1):31-56.
• [2]Chandna SM, Schulz J, Lawrence C, Greenwood RN, Farrington K. Is there a rationale for rationing chronic dialysis? A hospital based cohort study of factors affecting survival and morbidity. BMJ. 1999; 318(7178):217-223.
• [3]Weisbord SD, Fried LF, Arnold RM, Fine MJ, Levenson DJ, Peterson RA, Switzer GE. Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol. 2005; 16(8):2487-2494.
• [4]Chilcot J, Wellsted D, Farrington K. Depression in end-stage renal disease: current advances and research. Semin Dial. 2010; 23(1):74-82.
• [5]Wang PL, Watnick SG. Depression: a common but underrecognized condition associated with end-stage renal disease. Semin Dial. 2004; 17(3):237-241.
• [6]Chilcot J, Davenport A, Wellsted D, Firth J, Farrington K. An association between depressive symptoms and survival in incident dialysis patients. Nephrol Dial Transplant. 2011; 26(5):1628-1634.
• [7]Drayer RA, Piraino B, Reynolds CF, Houck PR, Mazumdar S, Bernardini J, Shear MK, Rollman BL. Characteristics of depression in hemodialysis patients: symptoms, quality of life and mortality risk. Gen Hosp Psychiatry. 2006; 28(4):306-312.
• [8]Cukor D, Rosenthal DS, Jindal RM, Brown CD, Kimmel PL. Depression is an important contributor to low medication adherence in hemodialyzed patients and transplant recipients. Kidney Int. 2009; 75(11):1223-1229.
• [9]Weisbord SD, Mor MK, Sevick MA, Shields AM, Rollman BL, Palevsky PM, Arnold RM, Green JA, Fine MJ. Associations of depressive symptoms and pain with dialysis adherence, health resource utilization, and mortality in patients receiving chronic hemodialysis. Clin J Am Soc Nephrol. 2014; 9(9):1594-1602.
• [10]Rabindranath K, Butler J, Macleod A, Roderick P, Wallace S, Daly C. Physical measures for treating depression in dialysis patients. Cochrane Database Syst Rev. 2005;2.
• [11]Blumenfield M, Levy NB, Spinowitz B, Charytan C, Beasley CM, Dubey AK, Solomon RJ, Todd R, Goodman A, Bergstrom RF. Fluoxetine in depressed patients on dialysis. Int J Psychiatry Med. 1997; 27(1):71-80.
• [12]Wuerth D, Finkelstein SH, Ciarcia J, Peterson R, Kliger AS, Finkelstein FO. Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. Am J Kidney Dis. 2001; 37(5):1011-1017.
• [13]Kennedy SH, Craven JL, Rodin GM. Major depression in renal dialysis patients: an open trial of antidepressant therapy. J Clin Psychiatry. 1989; 50(2):60-63.
• [14]Koo JR, Yoon JY, Joo MH, Lee HS, Oh JE, Kim SG, Seo JW, Lee YK, Kim HJ, Noh JW. Treatment of depression and effect of antidepression treatment on nutritional status in chronic hemodialysis patients. Am J Med Sci. 2005; 329(1):1.
• [15]Atalay H, Solak Y, Biyik M, Biyik Z, Yeksan M, Uguz F, Guney I, Tonbul HZ, Turk S. Sertraline treatment is associated with an improvement in depression and health-related quality of life in chronic peritoneal dialysis patients. Int Urol Nephrol. 2010; 42(2):527-536.
• [16]Levy NB, Blumenfield M, Beasley CM, Dubey AK, Solomon RJ, Todd R, Goodman A, Bergstrom RR. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. Gen Hosp Psychiatry. 1996; 18(1):8-13.
• [17]Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3–5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012; 27(10):3736-3745.
• [18]Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H et al.. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 373(9665):746-758.
• [19]Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS et al.. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002; 288(6):701-709.
• [20]van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1993; 24(3):203-220.
• [21]Schwenk MH, Verga MA, Wagner JD. Hemodialyzability of sertraline. Clin Nephrol. 1995; 44(2):121-124.
• [22]Brooks R. EuroQol: the current state of play. Health Policy. 1996; 37(1):53-72.
• [23]Beck A, Steer R, Brown G. Manual for the BDI-II. Psychological Corporation, San Antonio, TX; 1996.
• [24]Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59 Suppl 20:22-33.
• [25]Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134:382-389.
• [26]Kroenke K, Spitzer RL. The PHQ-9: A new depression diagnostic and severity measure. Psychiat Ann. 2002; 32(9):509-515.
• [27]Folstein MF, Folstein SE, Mchugh PR. Mini-Mental State - Practical Method for Grading Cognitive State of Patients for Clinician. J Psychiat Res. 1975; 12(3):189-198.
• [28]Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry. 2007; 4(7):28-37.
• [29]Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-383.
• [30]Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res. 1994; 3(5):329-338.
• [31]EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990; 16(3):199-208.
• [32]Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010; 340:c869.
• [33]Dube P, Kurt K, Bair MJ, Theobald D, Williams LS. (2010). The p4 screener: evaluation of a brief measure for assessing potential suicide risk in 2 randomized effectiveness trials of primary care and oncology patients. Prim Care Companion J Clin Psychiatry, 12(6).